A recent review highlights inflammation’s dual role in cancer progression and how emerging tools like AI and imaging biomarkers are enhancing personalized immunotherapy.
Key Details
- 1Chronic inflammation promotes tumorigenesis, survival, and therapy resistance, but can also suppress cancer depending on context.
- 2Key pathways: NF-κB, STAT3, IL-6, COX-2, and specific immune cells modulate the tumor microenvironment.
- 3Immunotherapies show varying efficacy (20–40% response rates); biomarkers like CRP, IL-6, and imaging data are key for patient stratification.
- 4Combination strategies (immunotherapy plus anti-inflammatories or microbiome modulators) are under clinical investigation.
- 5AI models incorporating imaging and multi-omic data are enabling real-time treatment personalization; Stanford’s 2024 model integrates imaging/text.
- 6Emerging tools include liquid biopsies, single-cell omics, gene editing, and nanotechnology for more precise disease monitoring.
Why It Matters
Understanding how inflammation drives cancer and therapy resistance is crucial for radiology, especially as integration of imaging, AI, and novel biomarkers underpins the move toward precision oncology. These advances offer new avenues for diagnosis, patient stratification, and monitoring treatment response using imaging and AI-driven tools.
Source
EurekAlert
Related News
•EurekAlert
Researchers Develop All-Optical Synapse for Neuromorphic Imaging Systems
A new artificial synapse, controlled entirely by light, enables in-sensor neuromorphic processing for more efficient and noise-resistant imaging systems.
•EurekAlert
Mayo Clinic Showcases Imaging AI and Early Cancer Detection Advances at ASCO 2026
Mayo Clinic researchers will present over 30 studies at ASCO 2026, highlighting new advances in imaging AI, data science, and early cancer detection.
•EurekAlert
AI-Simulation Approach Achieves 90% Faster Brain MRI with Minimal Data
A simulation-based AI method can reconstruct brain MRI scans with only 10% of the usual data, greatly reducing scan times.